Features Partner Sites Information LinkXpress
Sign In
Advertise with Us
RANDOX LABORATORIES

Novel Antisense Compound Reverses Alzheimer's Disease Symptoms in Mouse Models

By BiotechDaily International staff writers
Posted on 02 Jun 2014
Print article
An antisense oligonucleotide, which suppresses the mRNA required for synthesis of amyloid-beta protein precursor (AbetaPP), decreased AbetaPP expression and amyloid-beta protein (Abeta) production, and reversed Alzheimer's disease symptoms in mouse models.

Investigators at Saint Louis University (MO, USA) had shown previously that their OL-1 antisense compound rapidly crossed the blood-brain barrier, reversed learning and memory impairments, reduced oxidative stress, and restored brain-to-blood efflux of Abeta in the SAMP8 mouse model. These animals carry a natural mutation causing them to overproduce mouse amyloid beta.

In the current study, the investigators tested OL-1 in the Tg2576 Alzheimer's disease mouse model, which comprises animals that had been genetically engineered to overexpress a mutant form of the human amyloid beta precursor gene.

Results published in the May 2014 issue of the Journal of Alzheimer's Disease revealed that treatment of the Tg2576 mice with OL-1 produced the same reversal of Alzheimer's disease symptoms as had been observed earlier in the SAMP8 mice. Biochemical analyses of brain tissue taken from the treated animals showed significant reduction of AbetaPP signaling and a reduction of indicators of neuroinflammation.

"Our findings reinforced the importance of amyloid beta protein in the Alzheimer's disease process. They suggest that an antisense that targets the precursor to amyloid beta protein is a potential therapy to explore to reversing symptoms of Alzheimer's disease," said senior author Dr. Susan Farr, professor of geriatrics at Saint Louis University. "It reversed learning and memory deficits and brain inflammation in mice that are genetically engineered to model Alzheimer's disease. Our current findings suggest that the compound, which is called antisense oligonucleotide (OL-1), is a potential treatment for Alzheimer's disease."

Related Links:

Saint Louis University



Print article

Channels

Genomics/Proteomics

view channel
Image: The green-labeled cells show a basal cell carcinoma in mouse tail epidermis derived from a single mutant stem cell and expanding out of the normal epidermis stained in red (Photo courtesy of Adriana Sánchez-Danés, Université Libre de Bruxelles).

Stem Cells Not Progenitors Can Trigger Skin Cancer Growth

Cancer researchers have discovered that stem cells can initiate development of malignant skin tumors, while progenitor cells are limited to triggering only benign growths. A progenitor cell is similar... Read more

Biochemistry

view channel
Image: A space-filling model of the anticonvulsant drug carbamazepine (Photo courtesy of Wikimedia Commons).

Wastewater May Contaminate Crops with Potentially Dangerous Pharmaceuticals

Reclaimed wastewater used to irrigate crops is contaminated with pharmaceutical residues that can be detected in the urine of those who consumed such produce. Investigators at the Hebrew University... Read more

Lab Technologies

view channel
Image: A 3D nanofiber net formed by the supergelators to trap oil molecules (Photo courtesy of IBN at A*STAR / Institute of Bioengineering and Nanotechnology).

Effective Cleanup with Smart Material That Forms Oil-Trapping Net

Researchers have developed supergelators – an organic oil-scavenging material that rapidly forms a 3D net to trap oil molecules, gelatinizing into solidified masses that can be more easily removed from... Read more

Business

view channel

Sartorius Acquires US Start-up ViroCyt

Sartorius AG (Göttingen, Germany), a pharmaceutical and laboratory equipment provider, has acquired ViroCyt Incorporated (Broomfield, CO, USA), a start-up in the field of rapid virus quantification, in a deal valued at approximately USD 16 million. ViroCyt’s automated platform integrates instruments, software and reagents... Read more
Copyright © 2000-2016 Globetech Media. All rights reserved.